i-alveolar soft part sarcoma, I-Atezolizumab, uhlelo oluyisisekelo senzwa, I-Genentech, I-Tecentriq
I-Atezolizumab igunyazwe yi-FDA ye-alveolar soft tissue sarcoma
Dec 2022: I-Atezolizumab (Tecentriq, Genentech, Inc.) igunyazwe yi-Food and Drug Administration (FDA) yeziguli zabantu abadala kanye nezingane ezinengxenye ethambile ye-alveolar engabonakali noma ene-metastatic esineminyaka engu-2 ubudala.
I-Atezolizumab, Bevacizumab, nivolumab, I-Regorafenib, I-Stivarga, I-Tecentriq
Izidakamizwa ezigunyazwe ukwelapha umdlavuza wesibindi
Dec 2021: Izidakamizwa ezilandelayo zivunyelwe kusukela manje ukuze zelashwe umdlavuza wesibindi:. Sicela uhlole imininingwane yokunquma ngaphambi kokuthatha umuthi. I-Atezolizumab Avastin (Bevacizumab) i-Bevacizumab Cabometyx (Cabozantinib-SM..
I-Atezolizumab, I-Genentech, I-NSCLC, I-Tecentriq, Izinhlelo zeVentana Medical, I-VENTANA PD-L1
I-Atezolizumab igunyazwe yi-FDA njengokwelashwa kwe-adjuvant kumdlavuza wamaphaphu ongewona omncane
Nov 2021: I-Food and Drug Administration igunyaze i-atezolizumab (Tecentriq, Genentech, Inc.) yokwelashwa kwe-adjuvant ezigulini ezinomdlavuza wamaphaphu we-cell ongewona omncane wesigaba II kuya ku-III (NSCLC) izimila zazo eziqukethe i-PD-L1 inkulumo.